Moreover, stratification of patients by CD24 expression revealed an increased relapse‐free survival for patients with ovarian cancer and an overall survival advantage for patients with breast cancer with lower CD24 expression, and anti‐SIGLEC10 rescued the macrophage capability to limit tumor growth.340. This evidence concerns the gene CD24 and ovarian carcinoma.